References
- Molica S, Matutes E, Tam C, et al. Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. Hematol Oncol. 2020;38(2):129–136.
- Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the Phase 3 RESONATE-2 Study. Leukemia. 2020;34(3):787–798.
- Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879.
- Strati P, Parikh SA, Chaffee KC, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178(3):394–402.
- Gordon MJ, Churnetski M, Alqahtani H, et al. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018;124(15):3192–3200.
- Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019; 134(22):1919–1928.
- Williams AM, Baran AM, Schaffer M, et al. Significant weight gain in CLL patients treated with ibrutinib: a potentially deleterious consequence of therapy. Am J Hematol. 2020;95(1):E16–E18.
- Iurlo A, Orsi E, Cattaneo D, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget. 2015;6(32):33944–33945.
- Winer DA, Winer S, Chng MHY, et al. B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. Cell Mol Life Sci. 2014;71(6):1033–1043.
- Skrabs C, Pickl WF, Perkmann T, et al. Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia. J Clin Pharm Ther. 2018;43(1):145–149.
- Lee HJ, Lee SR, Choi EK, et al. Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation. J Am Heart Assoc. 2019;8(23):e012771.
- Lau DH, Nattel S, Kalman JM, et al. Response by Lau et al to Letters Regarding Article, "Modifiable Risk Factors and Atrial Fibrillation". Circulation. 2018;137(14):1534–1535.
- Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298–1307.
- Misselbeck K, Parolo S, Lorenzini F, et al. A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome. Nat Commun. 2019;10(1):5215.